Based on the data of clinical follow-up, attended in Chicago at the largest public conference of oncologists, the use of the drug " Significantly, that in five years 88 thousand patients, who received leniency, were still alive. Diagnosis of the drug is directed to non-cancerous cell carcinoma of the legends, transferring UNN to Aljazeera.

Details The use of the drug "

Cancer of the legends is a form of illness that causes the most deaths, approximately 1.8 million deaths worldwide. Excitement, expanded by the AstraZeneca pharmaceutical group, directed to the first type of cancer of the legends in patients who suffer from the so-called non-cancerous cancer, the widest type, and may have the first type of mutations.

Qi mutations in the so-called epidermal growth factor receptor (EGFR) affect 10 to 25 patients for cancer in the United States and Europe and 30 to 40 patients in Asia. Nearly 680 participants in the early stages of illness from more than 20 countries of the world took part in the clinical trial. They operated on their lower back to remove the puffiness, then half of the patients took the drug today, and the other half received a placebo.

The result showed that taking the pills resulted in a 51-year reduction in the risk of death for prolapsed patients, equal to placebo. Five years later, 88 thousand patients who took the liquor were still alive, equal to 78 thousand patients who took placebo.

These data are " The drug helps to " In yoga words, close to a third of the recovery of non-cellular cancer can be operated on with yoga manifestations.

"

According to the press release of AstraZeneca, osimertinib is already licensed in dozens of countries for various indications, and close to 700,000 people have already taken yoga. Praise in the USA for the treatment of early stages in 2020 was based on the previous data, which showed an improvement in the survival rate of patients without illness, that time, which patient is alive without a recurrence of cancer.

But not all doctors accepted the treatment, and many of them checked the data on global survival, as they were presented at the meeting of the American Fellowship of Clinical Oncology, Herbst said. We voted on the need for screening of patients, to find out if they have an EGFR mutation. In a different way, behind yoga words, "

Ozimertinib, which binds to the receptor, has side effects that include strong susceptibility or diarrhea.

Antonina Gorohovska Dzherelo: UNN.